BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Four countries to boycott Eurovision 2026 over Israel’s inclusion - 2Australia’s post-Bondi crackdown accused of targeting pro-Palestinian voices
- 3Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- 4Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- 5Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Pick Your Number one sort of blossom
- NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- Best Getaway destination: Ocean side, Mountain, or City
- The Response to Self-improvement: Embracing a Development Outlook
- Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- Cocoa Prices Settle Lower on Expectations of Adequate Supplies
